Petra Langerbeins PhD, EHA 2019 – Results of the Phase III Double-blind Randomised CLL12 Trial
We are joined by Petra Langerbeins at the EHA annual meeting in Amsterdam to discuss her presentation on ibrutinib versus placebo in patients with asymptomatic, treatment-naive early-stage chronic lymphocytic leukaemia (CLL): primary endpoint results of the phase III double-blind randomised CLL12 trial.
1. What is the current treatment paradigm for patients with asymptomatic early-stage chronic lymphocytic leukaemia (CLL)? (0:05)
2. What are the limitations of available treatment options for people with asymptomatic high-risk CLL? (0:30)
3. Could you tell us a little about the findings of the phase III study of ibrutinib in this treatment setting? (1:06)
4. Which patients are most likely to respond to ibrutinib and in which is it contraindicated? (2:50)
5. What is the safety profile of ibrutinib and how can adverse events be managed? (3:55)
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Leukaemia
Massimo Breccia, ASH 2022: Asciminib for patients with chronic myeloid leukaemia, the ASC4OPT study
The ASC4OPT study aims to potentially optimize dosing levels of asciminib in patients with chronic myeloid leukaemia in the chronic phase that have previously been treated with 2 lines of tyrosine kinase inhibitors. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the ASCEMBL findings, what we […]
Massimo Breccia, ASH 2022: The limitations of tyrosine kinase inhibitors in chronic myeloid leukaemia and approval status of asciminib
Tyrosine kinase inhibitors (TKIs) are the standard of care in the treatment of chronic myeloid leukaemia (CML). Asciminib is the first BCR::ABL1 inhibitor that functions by specifically targeting the ABL myristoyl pocket. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the limitations of TKIs in the […]
Jorge Cortes, ASH 2022: IDH1 inhibitors in the treatment of IDH1-mutant acute myeloid leukaemia – results from a phase II pivotal clinical trial
Professor Jorge Cortes (Georgia Cancer Center, GA, USA) discusses the results from a recent clinical trial that were presented at ASH 2022. Abstract 2757: ‘Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial‘ Disclosures: Jorge Cortes is a […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!